212 related articles for article (PubMed ID: 9703859)
21. Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Moehler M; Eimermacher A; Siebler J; Höhler T; Wein A; Menges M; Flieger D; Junginger T; Geer T; Gracien E; Galle PR; Heike M
Br J Cancer; 2005 Jun; 92(12):2122-8. PubMed ID: 15942629
[TBL] [Abstract][Full Text] [Related]
22. Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide.
Taal BG; Teller FG; ten Bokkel Huinink WW; Boot H; Beijnen JH; Dubbelman R
Ann Oncol; 1994 Jan; 5(1):90-2. PubMed ID: 8172800
[TBL] [Abstract][Full Text] [Related]
23. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin, mitomycin-C, 5-fluorouracil and leucovorin combination chemotherapy (l-FCM) in locally advanced unresectable or metastatic gastric carcinoma: a phase-II study.
Bobbio-Pallavicini E; Tacconi F; Porta C; Brambilla G; Mainardi E; Bianchessi C; Moroni M
Oncol Rep; 2001; 8(1):167-71. PubMed ID: 11115592
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy.
di Bartolomeo M; Bajetta E; de Braud F; Bochicchio AM; Gebbia V; Bozzetti F; Doci R; Bonfanti G; Cozzaglio L
Oncology; 1995; 52(1):41-4. PubMed ID: 7800341
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
27. New developments in the treatment of gastric carcinoma.
Wilke H; Preusser P; Fink U; Achterrath W; Meyer HJ; Stahl M; Lenaz L; Meyer J; Siewert JR; Geerlings H
Semin Oncol; 1990 Feb; 17(1 Suppl 2):61-70. PubMed ID: 2305269
[TBL] [Abstract][Full Text] [Related]
28. [A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Takeda S; Taguchi T; Ohta J; Kurihara M; Abe T; Ohtani T; Yonemura Y; Ohno T; Hirabayashi N; Nakano S
Gan To Kagaku Ryoho; 1995 Jun; 22(7):903-10. PubMed ID: 7793996
[TBL] [Abstract][Full Text] [Related]
29. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.
González-Barón M; Feliu J; Espinosa E; García-Girón C; Chacón I; Garrido P; Colmenarejo A; Ordóñez A; Zamora P
Cancer Chemother Pharmacol; 1995; 36(3):255-8. PubMed ID: 7781148
[TBL] [Abstract][Full Text] [Related]
30. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Scheithauer W; Depisch D; Kornek G; Pidlich J; Rosen H; Karall M; Prochaska M; Ernst A; Sebesta C; Eckhardt S
Cancer; 1994 Mar; 73(6):1562-8. PubMed ID: 8156482
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Rosati G; Cordio S; Caputo G; Condorelli S; Germano D; Mattina M; Amadio P; Reggiardo G; Manzione L
J Chemother; 2007 Oct; 19(5):570-6. PubMed ID: 18073157
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Constenla M; Garcia-Arroyo R; Lorenzo I; Carrete N; Campos B; Palacios P
Gastric Cancer; 2002; 5(3):142-7. PubMed ID: 12378340
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer.
Bokemeyer C; Hartmann JT; Lampe CS; Clemens MR; Quietzsch D; Forkmann L; Kanz L
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-96-S19-100. PubMed ID: 9427277
[TBL] [Abstract][Full Text] [Related]
36. [Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
Wang ZH; Guo J; Chen Z; Li CZ; Sheng LJ; Zhou DG; Liu B; Liu J; Wang QC; Zhang EN
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):389-91. PubMed ID: 18953843
[TBL] [Abstract][Full Text] [Related]
37. High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
Loeffler TM; Hausamen TU
J Infus Chemother; 1996; 6(3):137-40. PubMed ID: 9229325
[TBL] [Abstract][Full Text] [Related]
38. A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Stöger H; Bauernhofer T; Schmid M; Ploner F; Moser R; Derstvenscheg E; Steindorfer P; Wilders-Truschnig M; Kuss I; Samonigg H
Cancer Chemother Pharmacol; 1994; 35(2):174-8. PubMed ID: 7987997
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Yeh KH; Lu YS; Hsu CH; Lin JF; Hsu C; Kuo SH; Li SJ; Cheng AL
Oncology; 2005; 69(1):88-95. PubMed ID: 16088236
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
